Showing 3151-3160 of 5773 results for "".
- Alcon Launches Clareon Presbyopia Correcting IOLs in Indiahttps://modernod.com/news/alcon-launches-clareon-presbyopia-correcting-iols-in-india/2482160/Alcon announced the launch of the Clareon family of IOLs in India. Clareon is designed to deliver consistent visual outcomes and exceptional clarity that lasts and is features a glistening-free IOL material that has among the lowest levels of haze and subsurface nanoglist
- MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucomahttps://modernod.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging com
- Lucentis Biosimilar Receives Marketing Authorization from the Saudi Food & Drug Authorityhttps://modernod.com/news/lucentis-biosimilar-receives-marketing-authorization-from-the-saudi-food-drug-authority/2482156/Formycon AG and MS Pharma announced that Ravegza (FYB201), a biosimilar to Lucentis (ranibizumab), has received marketing authorization from the Saudi Food & Drug Authority. Ravegza is approved in Saudi Arabia for the treatment of patients with wet age-related macular
- Apellis Appoints Philip Ferrone, MD, as Chief Medical Retina Advisorhttps://modernod.com/news/apellis-appoints-philip-ferrone-md-as-chief-medical-retina-advisor/2482154/Apellis Pharmaceuticals announced that retina specialist Philip Ferrone, MD, will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Reti
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- AcrySof IQ Vivity and Clareon Vivity EDOF IOLs Reach 1 Million Implants Milestonehttps://modernod.com/news/acrysof-iq-vivity-and-clareon-vivity-edof-iols-reach-1-million-implants-milestone/2482147/Alcon announced that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) IOLs have surpassed more than 1 million implants worldwide. Vivity is the most implanted EDOF IOL globally, according to Alcon.[1] “We are proud to celebrate
- Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officerhttps://modernod.com/news/vital-tears-appoints-joseph-tauber-md-as-chief-medical-officer/2482146/Vital Tears, a provider of autologous serum tears, has announced the appointment of Joseph Tauber, MD, as its Chief Medical Officer (CMO). In his new role, Dr. Tauber will lead Vital Tears’ research and development initiatives, provide physician education and training, and&nb
- Neurolenses Demonstrate Headache Relief in New Studyhttps://modernod.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/Neurolens announced results of a company-sponsored study evaluating the impact of Neurolens prescription lenses on individuals with headaches. The six-item Headache Impact Test (H
- Formosa Receives FDA Approval for Clobetasol Formulation for Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/formosa-pharmaceuticals-receives-fda-approval-for-clobetasol-formulation-for-treatment-of-postoperative-inflammation-and-pain/2482142/Formosa Pharmaceuticals and AimMax Therapeutics announced that the FDA has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of postoperative inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspensi